CD33 and cancer: In our study, however, the CD33+ cell density did not change with age, while a high level of CD33+ infiltration combined with expression of PD-L1 <1% TCs significantly correlated with better OS in elderly patients, indicating a secondary role of CD33+ cells in limiting cancer-promoting inflammation and tumor growth [19].